The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling
angiogenesis, HCC, immunotherapy, response, ß-catenin
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2022
|
| In: |
Cancer reports
Year: 2022, Jahrgang: 5, Heft: 3, Pages: 1-4 |
| ISSN: | 2573-8348 |
| DOI: | 10.1002/cnr2.1493 |
| Online-Zugang: | Resolving-System, kostenfrei: http://dx.doi.org/10.1002/cnr2.1493
|
| Verfasserangaben: | Sebastian Krug, Laura Mattheis, Monika Haemmerle, Jonas Rosendahl,Joerg Kleeff, Patrick Michl |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1799833356 | ||
| 003 | DE-627 | ||
| 005 | 20230118155405.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220420s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cnr2.1493 |2 doi | |
| 035 | |a (DE-627)1799833356 | ||
| 035 | |a (DE-599)KXP1799833356 | ||
| 035 | |a (OCoLC)1361713631 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Krug, Sebastian |d 1985- |e VerfasserIn |0 (DE-588)1014103975 |0 (DE-627)705168034 |0 (DE-576)348318332 |4 aut | |
| 245 | 1 | 4 | |a The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling |c Sebastian Krug, Laura Mattheis, Monika Haemmerle, Jonas Rosendahl,Joerg Kleeff, Patrick Michl |
| 264 | 1 | |c 2022 | |
| 300 | |b Illustrationen, Diagramme | ||
| 300 | |a 4 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlich am 26. Juli 2021 | ||
| 520 | |a angiogenesis, HCC, immunotherapy, response, ß-catenin | ||
| 540 | |q DE-3 |a Namensnennung 4.0 International |f CC BY 4.0 |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 700 | 1 | |a Roth, Laura |d 1992- |e VerfasserIn |0 (DE-588)1245623915 |0 (DE-627)1777306760 |4 aut | |
| 700 | 1 | |a Hämmerle, Monika |d 1983- |e VerfasserIn |0 (DE-588)1022853430 |0 (DE-627)717318958 |0 (DE-576)366078615 |4 aut | |
| 700 | 1 | |a Rosendahl, Jonas |d 1977- |e VerfasserIn |0 (DE-588)1020755024 |0 (DE-627)69133434X |0 (DE-576)361950845 |4 aut | |
| 700 | 1 | |a Kleeff, Jörg H. |d 1969- |e VerfasserIn |0 (DE-588)115669248 |0 (DE-627)077395271 |0 (DE-576)290010071 |4 aut | |
| 700 | 1 | |a Michl, Patrick |d 1971- |e VerfasserIn |0 (DE-588)121336328 |0 (DE-627)081239203 |0 (DE-576)292654677 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer reports |d Medford, MA : Wiley, 2018 |g 5(2022), 3, Artikel-ID e1493, Seite 1-4 |h Online-Ressource |w (DE-627)1014116775 |w (DE-600)2920367-3 |w (DE-576)499937155 |x 2573-8348 |7 nnas |a The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling |
| 773 | 1 | 8 | |g volume:5 |g year:2022 |g number:3 |g elocationid:e1493 |g pages:1-4 |g extent:4 |a The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cnr2.1493 |x Resolving-System |z kostenfrei |
| 951 | |a AR | ||
| 992 | |a 20221202 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 121336328 |a Michl, Patrick |m 121336328:Michl, Patrick |p 6 |y j | ||
| 998 | |g 1014103975 |a Krug, Sebastian |m 1014103975:Krug, Sebastian |p 1 |x j | ||
| 999 | |a KXP-PPN1799833356 |e 4223359975 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Sebastian Krug, Laura Mattheis, Monika Haemmerle, Jonas Rosendahl,Joerg Kleeff, Patrick Michl"]},"language":["eng"],"person":[{"display":"Krug, Sebastian","given":"Sebastian","role":"aut","family":"Krug"},{"role":"aut","family":"Roth","given":"Laura","display":"Roth, Laura"},{"family":"Hämmerle","role":"aut","display":"Hämmerle, Monika","given":"Monika"},{"family":"Rosendahl","role":"aut","display":"Rosendahl, Jonas","given":"Jonas"},{"role":"aut","family":"Kleeff","display":"Kleeff, Jörg H.","given":"Jörg H."},{"display":"Michl, Patrick","given":"Patrick","family":"Michl","role":"aut"}],"recId":"1799833356","note":["Online veröffentlich am 26. Juli 2021"],"title":[{"title":"The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling","title_sort":"impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signaling"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"noteIll":"Illustrationen, Diagramme","extent":"4 S."}],"id":{"doi":["10.1002/cnr2.1493"],"eki":["1799833356"]},"relHost":[{"recId":"1014116775","title":[{"title_sort":"Cancer reports","title":"Cancer reports"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["1014116775"],"issn":["2573-8348"],"zdb":["2920367-3"],"doi":["10.1002/(ISSN)2573-8348"]},"origin":[{"publisher":"Wiley","dateIssuedDisp":"2018-","dateIssuedKey":"2018","publisherPlace":"Medford, MA"}],"language":["eng"],"part":{"extent":"4","pages":"1-4","issue":"3","text":"5(2022), 3, Artikel-ID e1493, Seite 1-4","year":"2022","volume":"5"},"note":["Gesehen am 28.06.21"],"pubHistory":["Volume 1, issue 1 (June 2018)-"],"disp":"The impact of atezolizumab and bevacizumab in hepatocellular carcinoma with activated ß-catenin signalingCancer reports","type":{"media":"Online-Ressource","bibl":"periodical"}}],"origin":[{"dateIssuedDisp":"2022","dateIssuedKey":"2022"}]} | ||
| SRT | |a KRUGSEBASTIMPACTOFAT2022 | ||